Katie Newhall is the Vice President, Translational Clinical Development at Cellectis.She has an established record of leading cross-functional teams for biomarker discovery/development and translational research. While her current focus is in immuno-oncology, she has a diverse background in multiple disease indications. Katie Newhall has an extensive experience in projects in the discovery phase as well as early and late phase clinical trials, including clinical assay validation and qualification. She has attended Biomarkers US as a key speaker.